109 related articles for article (PubMed ID: 1672520)
21. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
22. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells.
Borrel MN; Fiallo M; Priebe W; Garnier-Suillerot A
FEBS Lett; 1994 Dec; 356(2-3):287-99. PubMed ID: 7805856
[TBL] [Abstract][Full Text] [Related]
24. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein.
Roepe PD; Wei LY; Cruz J; Carlson D
Biochemistry; 1993 Oct; 32(41):11042-56. PubMed ID: 8105888
[TBL] [Abstract][Full Text] [Related]
25. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
26. [A new method for the intravital assessment of the functional activity of the membrane transporters performing the efflux of antitumor preparations from the cells of solid tumor specimens].
Bogush TA; Smirnova GB; Bogush EA; Robert J
Antibiot Khimioter; 1999; 44(2):19-24. PubMed ID: 10202553
[TBL] [Abstract][Full Text] [Related]
27. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation.
Piwnica-Worms D; Rao VV; Kronauge JF; Croop JM
Biochemistry; 1995 Sep; 34(38):12210-20. PubMed ID: 7547962
[TBL] [Abstract][Full Text] [Related]
28. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
Evans CH; Baker PD
Cancer Res; 1992 Nov; 52(21):5893-9. PubMed ID: 1356622
[TBL] [Abstract][Full Text] [Related]
29. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein.
Shapiro AB; Ling V
Eur J Biochem; 1998 May; 254(1):181-8. PubMed ID: 9652412
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
31. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site.
Kajiji S; Talbot F; Grizzuti K; Van Dyke-Phillips V; Agresti M; Safa AR; Gros P
Biochemistry; 1993 Apr; 32(16):4185-94. PubMed ID: 7682843
[TBL] [Abstract][Full Text] [Related]
32. Saturable P-glycoprotein kinetics assayed by fluorescence studies of drug efflux from suspended human KB8-5 cells.
Ghauharali RI; Westerhoff HV; Dekker H; Lankelma J
Biochim Biophys Acta; 1996 Jan; 1278(2):213-22. PubMed ID: 8593279
[TBL] [Abstract][Full Text] [Related]
33. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane.
Altenberg GA; Vanoye CG; Horton JK; Reuss L
Proc Natl Acad Sci U S A; 1994 May; 91(11):4654-7. PubMed ID: 7910961
[TBL] [Abstract][Full Text] [Related]
34. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
35. Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells.
Doige CA; Sharom FJ
Biochim Biophys Acta; 1992 Aug; 1109(2):161-71. PubMed ID: 1355667
[TBL] [Abstract][Full Text] [Related]
36. Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance.
Altenberg GA; Young G; Horton JK; Glass D; Belli JA; Reuss L
Proc Natl Acad Sci U S A; 1993 Oct; 90(20):9735-8. PubMed ID: 8105483
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
38. Swelling-activated chloride channels in multidrug-sensitive and -resistant cells.
Ehring GR; Osipchuk YV; Cahalan MD
J Gen Physiol; 1994 Dec; 104(6):1129-61. PubMed ID: 7699367
[TBL] [Abstract][Full Text] [Related]
39. In archaebacteria, there is a doxorubicin efflux pump similar to mammalian P-glycoprotein.
Miyauchi S; Komatsubara M; Kamo N
Biochim Biophys Acta; 1992 Oct; 1110(2):144-50. PubMed ID: 1356441
[TBL] [Abstract][Full Text] [Related]
40. Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance.
Chen VY; Posada MM; Zhao L; Rosania GR
Pharm Res; 2007 Nov; 24(11):2156-67. PubMed ID: 17668300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
